The last 12 months collaboration allowed Bavarian Nordic to produce positive data, and to demonstrate that its recombinant vaccines platform, MVA-BN, can be efficiently and consistently manufacture with the EBx cell line.
Bavarian Nordic is evaluating the EBx cell line as a potential alternative production technology to its existing CEF process for the manufacturing of several vaccine candidates.
Franck Grimaud, Vivalis CEO said: “These results confirm again that the EBx platform turns to be the reference cell substrate for poxvirus based vaccines production and is relevant for a wide range of therapeutics applications. We are strongly convinced that more and more companies will move from eggs to the EBx cell line in a foreseeable future”.